|
|
| |
 |
| |
|
| |
| Latest News |
Eli Lilly and Company Researchers Begin Working At New State-of-the-Art Lab Located in the Heart of New York City
>>more
|
|
|
|
 |
| |
ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company (NYSE:LLY), is committed
to advancing oncology care by developing a portfolio of targeted biologic treatments designed
to address the medical needs of patients with a variety of cancers. Founded in 1984, ImClone
has a rich culture of discovery and deep expertise in oncology. ImClone has several
investigational monoclonal antibodies in various stages of clinical development. ImClone's
research and clinical development capabilities are augmented by its expertise in the scale-up
and manufacturing of biologics. The company's state-of-the-art FDA-approved manufacturing
facilities provide it with one of the largest biologic manufacturing capacities in the world.
ImClone Systems became a wholly-owned subsidiary of Eli Lilly and Company on November 24,
2008. Read the press release
Additional information about Lilly is available at www.lilly.com
|
|
|
|
